ELVN insider trading — Enliven Therapeutics, Inc.
Over the last 90 days, insiders at Enliven Therapeutics, Inc. (ELVN) made 0 open-market purchases worth $0 and 1 open-market sale worth $607K, making them net sellers by $607K. The largest sale was by Garland J. Scott (Director), who sold 13,000 shares for $607K on Oct 1, 2026.
Updated Oct 16, 2026.
Recent ELVN insider transactions
Every Form 4 filed by Enliven Therapeutics, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Garland J. Scott | Director | M · Option exercise | Direct | 13,000 | $15.47 | $201K | Form 4 |
| Oct 1, 2026 | Garland J. Scott | Director | S · Sale | Direct | 13,000 | $46.67 | $607K | Form 4 |
| Sep 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M · Option exercise · 10b5-1 | Direct | 3,982 | $14.85 | $59K | Form 4 |
| Sep 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S · Sale · 10b5-1 | Direct | 6,018 | $50.35 | $303K | Form 4 |
| Sep 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M · Option exercise · 10b5-1 | Direct | 5,000 | $2.48 | $12K | Form 4 |
| Sep 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S · Sale · 10b5-1 | Direct | 5,000 | $50.35 | $252K | Form 4 |
| Aug 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S · Sale · 10b5-1 | Direct | 6,018 | $58.58 | $353K | Form 4 |
| Aug 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M · Option exercise · 10b5-1 | Direct | 5,000 | $2.48 | $12K | Form 4 |
| Aug 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S · Sale · 10b5-1 | Direct | 5,000 | $58.59 | $293K | Form 4 |
| Aug 4, 2026 | Derynck Mika K | Director | M · Option exercise · 10b5-1 | Direct | 158,795 | $10.84 | $1.72M | Form 4 |
| Aug 4, 2026 | Derynck Mika K | Director | S · Sale · 10b5-1 | Direct | 158,795 | $60.21 | $9.56M | Form 4 |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M · Option exercise · 10b5-1 | Direct | 1,072 | $2.48 | $3K | Form 4 |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S · Sale · 10b5-1 | Direct | 6,018 | $52.64 | $317K | Form 4 |
| Jul 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M · Option exercise · 10b5-1 | Direct | 5,000 | $2.48 | $12K | Form 4 |
| Jul 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S · Sale · 10b5-1 | Direct | 5,000 | $52.67 | $263K | Form 4 |
ELVN insider trading FAQ
Are insiders buying ELVN stock?
Not on the open market. In the last 90 days, Enliven Therapeutics, Inc. insiders made no open-market purchases, and 1 open-market sale totaling $607K. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading ELVN?
Recent sellers: Garland J. Scott.
Where does ELVN insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.